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Introduction
Bone fractures commonly result in prolonged disability and increased socioeconomic burden (1). In the 
United States, approximately 1.6 million bone fractures had impaired healing or progress to nonunion each 
year, further compromising the quality of  life and life expectancy of  many patients (2–4). Bone fracture inju-
ries disrupt marrow sinusoidal architecture and surrounding soft tissues, and blood clots form in the fracture 
area that initiate an early local inflammatory process (5). During this early hematoma period, endogenous 
mesenchymal progenitor cells (MPCs), recruited from multiple sources, undergo precisely regulated mul-
tidirectional differentiation to generate the cell lineages involved in bone regeneration and vascularization 
(6–8). In particular, MPC-derived chondrocytes and osteoblasts are essential cell populations necessary for 
cartilaginous and bony callus formation. Differentiation of  these cells along their lineages results in fracture 
union and return of  the mechanical integrity of  the skeleton (9, 10). After remodeling by osteoclasts, the 
fractured bone returns to its original cellular composition, morphologic structure, and biomechanical func-
tion (1). Fracture repair integrates cytokines, growth factors, and signaling pathways as well as progenitor 
cell proliferation and differentiation in a highly regulated process that leads to tissue regeneration (7, 11, 12). 
Although extensive studies define the cellular and molecular contributions to fracture repair, the effect of  
epigenetic regulations in fracture repair, particularly MPC differentiation, is still largely unknown.
In mammals, there are 3 epigenetic regulatory processes: DNA methylation, histone modification, and 
noncoding RNAs (13). Recent epigenome studies of  fracture patients revealed differential methylation loci 
associated with stem cell proliferation and differentiation in human mesenchymal stem cells, suggesting 
that DNA methylation is involved in fracture repair processes (14). DNA methylation is a well-character-
ized epigenetic modification in CpG-rich islands, leading to gene activation or suppression dependent on 
methylation patterns of  the promoter, enhancer, and gene body (15, 16). Three independent DNA meth-
We previously established that DNA methyltransferase 3b (Dnmt3b) is the sole Dnmt responsive 
to fracture repair and that Dnmt3b expression is induced in progenitor cells during fracture repair. 
In the current study, we confirmed that Dnmt3b ablation in mesenchymal progenitor cells (MPCs) 
resulted in impaired endochondral ossification, delayed fracture repair, and reduced mechanical 
strength of the newly formed bone in Prx1-Cre;Dnmt3bf/f (Dnmt3bPrx1) mice. Mechanistically, 
deletion of Dnmt3b in MPCs led to reduced chondrogenic and osteogenic differentiation in vitro. We 
further identified Rbpjκ as a downstream target of Dnmt3b in MPCs. In fact, we located 2 Dnmt3b 
binding sites in the murine proximal Rbpjκ promoter and gene body and confirmed Dnmt3b 
interaction with the 2 binding sites by ChIP assays. Luciferase assays showed functional utilization 
of the Dnmt3b binding sites in murine C3H10T1/2 cells. Importantly, we showed that the MPC 
differentiation defect observed in Dnmt3b deficiency cells was due to the upregulation of Rbpjκ, 
evident by restored MPC differentiation upon Rbpjκ inhibition. Consistent with in vitro findings, 
Rbpjκ blockage via dual antiplatelet therapy reversed the differentiation defect and accelerated 
fracture repair in Dnmt3bPrx1 mice. Collectively, our data suggest that Dnmt3b suppresses Notch 
signaling during MPC differentiation and is necessary for normal fracture repair.
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yltransferase (Dnmt) enzymes catalyze the transfer of  the methyl groups from S-adenosyl-L-methionine 
to cytosine in mammals. Dnmt1 is largely responsible for the maintenance of  genome-wide methylation 
during cell proliferation, whereas Dnmt3a and Dnmt3b primarily act as de novo Dnmts to establish unique 
DNA methylation patterns during development (13). The biological functions of  the de novo Dnmts in 
the regulation of  postnatal tissue repair processes are areas of  active investigation. Recent studies defined 
essential roles of  Dnmt3a and Dnmt3b in adult stem cell and hematopoietic stem cell differentiation (17, 
18) and in osteoclastogenesis (19). Moreover, our recent findings provided evidence that Dnmt3b is highly 
expressed in chondrocytes and progenitor cells of  fracture calluses and showed that Dnmt3b ablation in 
chondrocytes results in a chondrogenic differentiation defect and delayed fracture repair (20). This suggests 
that Dnmt3b has an essential role in regulation of  progenitor cell differentiation.
Therefore, this study explores the mechanism involved in the regulation of  MPC proliferation and differ-
entiation by Dnmt3b in both chondrogenic and osteogenic lineages during bone fracture healing. We show 
that ablation of  Dnmt3b is associated with reduced chondrogenic and osteogenic differentiation in MPCs, 
leading to decreased cartilaginous and bony callus formation and impaired fracture repair in mice that is due 
in part to the upregulation of  Rbpjκ expression. Importantly, we also show that Rbpjκ inhibition via dual 
antiplatelet therapy (DAPT) restores the Dnmt3b loss-of-function–induced (LOF-induced) MPC differenti-
ation defect in cell cultures and fracture healing delay in mice. To our knowledge these findings define new 
processes, pathways, and therapeutic targets to enhance fracture repair and restore skeletal mobility.
Results
Ablation of  Dnmt3b impairs endochondral ossification in fracture repair. We previously identified Dnmt3b as the 
most regulated epigenetic factor responsive to fracture repair process. Dnmt3b expression is induced and 
maintained in MPCs during fracture repair and gradually declined to a nondetectable level (20). Importantly, 
in the current study, we revealed a reduction of  Dnmt3b expression in fracture calluses 10 days after fracture 
(dpf) in high-fat diet–induced (HFD-induced) diabetic mice and aging mice (Supplemental Figure 1, A and 
B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.131816DS1), 
suggesting an essential role of  Dnmt3b in the regulation of  fracture repair. To comprehensively examine 
the role of  Dnmt3b in MPCs, we generated Prx1-Cre;Dnmt3bf/f (Dnmt3bPrx1) mice. Dnmt3bPrx1 mice displayed 
no obvious growth difference, with similar body weight and size (Supplemental Figure 2A), compared with 
Cre-negative littermates through 10 weeks of  age. Microcomputed tomography (micro-CT) analysis demon-
strated similar cortical thickness, tissue mineral density, trabecular thickness, and bone volume/total volume 
in both Dnmt3bPrx1 mice and littermate controls (Supplemental Figure 2, B–D), confirming our observations 
regarding relative normal bone development in Dnmt3bPrx1 mice. This suggests that loss of  Dnmt3b is either 
not critical or is compensated by the presence of  other Dnmts during bone development. We next assessed 
the Prx1-Cre–mediated Dnmt3b deletion efficiency in the tibiae of  adult Dnmt3bPrx1 mice and in fracture callus 
tissues. Western blot revealed substantial Dnmt3b reduction in protein lysates extracted from intact tibiae of  
10-week-old Dnmt3bPrx1 mice (Supplemental Figure 3A), indicating efficient Dnmt3b deletion in MPCs and 
their derived osteoblasts. As expected, IHC analyses of  fracture calluses 10 dpf in control mice and Dnmt3bPrx1 
mice also confirmed an efficient deletion of  Dnmt3b, specifically in MPCs (Supplemental Figure 3B).
We then performed tibia fracture on 10-week-old Dnmt3bPrx1 mice and their littermate controls to deter-
mine the effect of  Dnmt3b deletion on MPC proliferation and differentiation as well as on fracture repair in 
mice. Alcian blue/Hematoxylin/Orange G (ABH/OG) staining showed impaired fracture repair in Dnmt3b-
Prx1 mice. By 7 dpf, control mice had abundant chondrogenesis at the central hypoxic region of  the fracture, 
and robust osteogenesis and intramembranous bone formation in the periosteum adjacent to the fractures 
site. In contrast, fractures in Dnmt3bPrx1 mice were composed primarily of  undifferentiated mesenchyme tissue 
with limited chondrocyte cartilage or periosteal bone formation. Fractures in control mice had limited mes-
enchyme with the presence of  mature cartilage tissues and abundant bone formation 10 dpf, and the cartilage 
template was largely resorbed and replaced by secondary bone formation 14 dpf (Figure 1A). In comparison, 
mesenchymal tissue remained in fracture calluses 14 dpf in Dnmt3bPrx1 mice. Quantitative histomorphometry 
confirmed that there was less mesenchymal tissue in fracture calluses of  Dnmt3bPrx1 mice during the early stag-
es of  fracture healing and that Dnmt3bPrx1 mice exhibited a continued presence of  mesenchymal tissues and 
reduced cartilage and intramembranous bone formation through 14 dpf compared with control mice (Figure 
1B). Micro-CT analyses of  mineralized calluses in control mice showed robust bone formation surrounding 
the fracture site 10 and 14 dpf. In contrast, the fracture healing was significantly delayed in Dnmt3bPrx1 mice, as 
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shown by micro-CT, with reduced bony callus 10 and 14 dpf (Figure 1, C and D). Taken together, our in vivo 
findings revealed a reduced formation of  both cartilage and woven bone in the fractures of Dnmt3bPrx1 mice, 
suggesting that the process of  chondrogenic and osteogenic differentiation from mesenchymal progenitors is 
impaired in the absence of  Dnmt3b in MPCs during fracture repair.
Ablation of  Dnmt3b in vivo leads to delayed bone remodeling and poor healing. Since fracture repair is a highly 
integrated process, we next examined the effect of loss of Dnmt3b in MPCs on the later stages of healing. Tar-
trate-resistant acid phosphatase (TRAP) staining was performed to examine osteoclast-mediated remodeling 
14, 21, and 28 dpf. Consistent with our previous finding and others’ reports (1, 20–22), the total number of  
Figure 1. Ablation of Dnmt3b in mesenchymal progenitor cells reduced cartilaginous callus formation and bony callus ossification during fracture 
repair. (A) Alcian blue/Hematoxylin/Orange G (ABH/OG) staining of fracture callus sections of Dnmt3bPrx1 mice and control mice at the indicated times (n 
= 5). Scale bar: 500 μm. (B) Histomorphometry quantification of the mesenchyme, cartilage, and bone areas was performed on ABH/OG-stained fracture 
callus sections of Dnmt3bPrx1 mice and control mice at the indicated times (n = 5). (C) Microcomputed tomography assessment of mineralized bone in frac-
ture calluses of Dnmt3bPrx1 mice and control mice at the indicated times (n = 5). (D) Quantification of bony callus volumes in Dnmt3bPrx1 mice and control 
mice 10 and 14 days after fracture (dpf). Data are presented as mean ± SD. *P < 0.05 by 2-way ANOVA test.
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TRAP-positive cells peaked 14 dpf in the calluses of control mice and gradually decreased to an undetectable 
level 28 dpf. However, fractures of Dnmt3bPrx1 mice displayed a disparate pattern of osteoclast. TRAP-positive 
cell staining peaked 21 dpf and remained abundant in the calluses of Dnmt3bPrx1 mice throughout the 28 dpf (Fig-
ure 2A), leading to increased osteoclast surface per bone surface 21 and 28 dpf (Figure 2B). More importantly, 
torsion testing performed on fractured tibiae of Dnmt3bPrx1 mice and control mice 28 dpf showed that despite 
comparable bone callus volume 28 dpf, the Dnmt3bPrx1 mutant fractures had significantly lower mechanical prop-
erties, including bone strength (33% reduction), bone stiffness (25% reduction), and bone toughness (50% reduc-
tion) compared with control mice (Figure 2C). Collectively, these in vivo data show that Dnmt3b deficiency in 
MPCs not only impairs the formation of cartilaginous and bony callus, but also affects later events, including 
bone remodeling by osteoclasts and the restoration of biomechanical strength.
Dnmt3b ablation reduces MPC differentiation through upregulation of  Rbpjκ-mediated Notch pathway. To 
understand the molecular events related to the delay in fracture healing calluses of  Dnmt3bPrx1 mice, we 
examined chondrogenic differentiation using limb bud–derived MPCs isolated from E11.5 Dnmt3bPrx1 
embryos and control embryos, and osteogenic differentiation on bone marrow–derived MPCs isolated from 
10-week-old Dnmt3bPrx1 mice and their littermate controls. Real-time qPCR results confirmed the efficient 
deletion of  Dnmt3b in MPCs from either limb bud or bone marrow (Figure 3, C and F). Of  note, Dnmt3b 
Figure 2. Ablation of Dnmt3b in mesenchymal progenitor cells led to delayed bone callus remodeling and decreased biomechanical properties of the newly 
formed bone during fracture repair. (A) Tartrate-resistant acid phosphatase (TRAP) staining of fracture callus sections of Dnmt3bPrx1 mice and control mice 
at the indicated times (n = 5). Scale bar: 200 μm. (B) Histomorphometry analysis of osteoclast surface per bone surface (Oc. S/BS) was performed on TRAP 
staining of Dnmt3bPrx1 and control fractures at the indicated times (n = 5). (C) Biomechanical torsion testing was performed on fractured tibiae of Dnmt3bPrx1 
mice and control mice 28 days after fracture (dpf). Maximum torque, torsional rigidity, and energy to maximum were measured and calculated to represent 
the bone strength, bone stiffness, and bone toughness (n = 10). Data are presented as mean ± SD. *P < 0.05 by 2-way ANOVA test (B) and Student’s t test (C).
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deletion did not affect the colony-forming ability from bone marrow–adherent stromal cells (Supplemental 
4A). Similar numbers of  type I colony-forming–unit fibroblasts, about 60 per 1.5 × 106 marrow cells, were 
identified in the bone marrow of  Dnmt3bPrx1 mice and control mice (Supplemental Figure 4B), suggesting 
that the population of  MPCs and its proliferation capacity were maintained in Dnmt3bPrx1 mice. We next 
examined the MPC differentiation potential in vitro and found that following exposure to chondrogenic 
culture medium for 3 days, MPCs from control limb buds differentiated into chondrocytes and deposited 
a large amount of  cartilage matrix, as reflected by intense Alcian blue staining on the micromass cultures. 
However, ABH staining was substantially reduced in limb bud–derived MPCs from mice with Dnmt3b 
deficiency (Figure 3, A and B). In addition, the gene expression studies showed that the chondrogenesis 
master gene, Sox9, was decreased in limb bud–derived MPCs of  Dnmt3bPrx1 mice, as were the other key 
chondrocyte markers, Col2a1 and Agc1 (Figure 3C), indicating diminished chondrogenic differentiation 
capacity in MPCs of  Dnmt3bPrx1 mice.
In an analogous manner, bone marrow–derived MPCs from Dnmt3bPrx1 mice had reduced osteogenic 
differentiation (alkaline phosphatase [ALP] staining) and bone mineral deposition (Alizarin red staining) 
after 7 and 21 days of  osteogenic differentiation compared with bone marrow–derived MPCs from con-
trol mice (Figure 3, D and E). Moreover, the osteogenic master gene, Sp7, as well as Runx2 and Alp were 
decreased in bone marrow–derived MPCs of  Dnmt3bPrx1 mice compared with bone marrow–derived MPCs 
of  control mice (Figure 3F). Altogether, deletion of  Dnmt3b in vitro led to reduced MPC chondrogenic 
and osteogenic differentiation, but the cell proliferation was largely unaffected.
The Notch signaling pathway is a key regulator of  mesenchymal stem cells differentiation. Active Notch 
signaling maintains MPCs in a progenitor state and inhibits differentiation, including chondrogenesis and 
osteogenesis (3, 23, 24). To determine if  Notch signaling is a target of  Dnmt3b, we isolated primary MPCs 
from E11.5 limb bud (Figure 4, A and B) and bone marrow (Figure 4, C and D) and performed real-time 
qPCR and Western blot to examine the RNA and protein levels of  Notch pathway–related genes. In limb bud–
derived MPCs, real-time qPCR analyses confirmed that Dnmt3b deficiency induced the expression of  Hey1 
and HeyL (Figure 4A), the critical downstream targets of  Notch pathway. Moreover, Western blot revealed 
that the expression of  Rbpjκ, a key modulator of  Notch, was upregulated in MPCs of  Dnmt3bPrx1 mice (Figure 
4B). Consistent with the findings in limb bud–derived MPCs, the Rbpjκ-mediated Notch pathway was also 
increased following loss of  Dnmt3b in bone marrow–derived MPCs, as was evident by the upregulation of  
Hey1, HeyL, and Rbpjκ in mRNA and protein levels in bone marrow–derived MPCs of  Dnmt3bPrx1 mice 
(Figure 4, C and D). Altogether, these data indicate that Dnmt3b LOF induces defects of  chondrogenic and 
osteogenic differentiation and results in the upregulation of  Rbpjκ-mediated Notch pathway in cells.
Mechanistically, with respect to Dnmt3b and Rbpjκ, we identified 2 Dnmt3b binding sites (CpG 
islands 1 and 2, indicated by the green box in Figure 5A) in the murine proximal Rbpjκ promoter and gene 
body regions (which is highly conserved across species; data not shown). Dnmt3b interaction with the 
2 binding sites was also shown by ChIP assays (Figure 5B), and Dnmt3b LOF indeed resulted in DNA 
methylation decreases of  19.25% (85.46% in control and 69.02% in Dnmt3b LOF) and 9.29% (74.74% 
in control and 67.78% in Dnmt3b LOF) in CpG islands 1 and 2, respectively (Supplemental Figure 5). 
Luciferase reporter assays further showed functional utilization of  the Dnmt3b binding sites in the murine 
progenitor line, C3H10T1/2 cells (Figure 5C). Dnmt3b LOF increased Rbpjκ promoter activity, whereas 
Dnmt3b GOF attenuated basal Rbpjκ activity in C3H10T1/2 cells (Figure 5C). To validate Rbpjκ as the 
critical downstream target of  Dnmt3b, C3H10T1/2 cells were infected with Rbpjκ lenti-shRNA in com-
bination with Dnmt3b LOF. Rbpjκ inhibition protected MPC differentiation potential by restoring Sox9 
and Sp7 expression levels in vitro (Figure 5D), demonstrating that Rbpjκ inhibition is able to reverse the 
chondrogenic and osteogenic differentiation defect mediated by Dnmt3b LOF. Indeed, in the Dnmt3b and 
Rbpjκ double LOF groups, both chondrocyte matrix deposition and osteoblast differentiation, assessed by 
ABH staining and ALP staining, respectively, were restored compared with the Dnmt3b LOF group and 
even maintained the same enhanced levels as Rbpjκ LOF (Figure 5, E and F). Consistently, gene expres-
sion levels of  chondrocyte matrix markers, Agc1 and Col2, as well as osteoblast differentiation markers, 
Alp and Spp1, were restored in C3H10T1/2 cells by inhibition of  Rbpjκ in C3H10T1/2 cells with Dnmt3b 
LOF (Figure 5G). Together with our in vivo finding that Dnmt3b LOF suppressed MPC differentiation 
and resulted in impaired fracture healing in mice, these data suggest a mechanism whereby the loss of  
Dnmt3b results in the upregulation of  Rbpjκ through hypomethylation of  Rbpjκ gene, leading to poor 
MPC differentiation and bone healing.
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Notch inhibition restores the decreased differentiation and fracture repair in Dnmt3bPrx1 mice. It is well 
known that Rbpjκ-mediated Notch pathway is a negative regulator during MPC chondrogenic and 
osteogenic differentiation (23, 25–27), and we previously demonstrated that transient Notch inhibition 
Figure 3. Dnmt3b deletion suppressed mesenchymal progenitor cell chondrogenic and osteogenic differentiation in vitro. Mesenchymal progenitor cell 
(MPC) were isolated from E11.5 limb bud of Dnmt3bPrx1 embryos and control embryos, followed with 3 days micromass culture in the maturation medium. 
(A) Alcian blue staining was performed on micromass cultures (n = 3). (B) Alcian blue staining intensity was measured using NIH ImageJ software (n = 3). (C) 
Real-time qPCR analyses were performed to determine the relative expression of Dnmt3b, Sox9, Col10a1, and Agc1 in the micromass. The mRNA levels were 
normalized to that of Actb and then were normalized to the control group (n = 3). (D) Bone marrow–derived MPCs were isolated from 10-week-old Dnmt3bPrx1 
mice and control mice and cultured in osteogenic medium for 4, 7, and 21 days. Alkaline phosphatase (ALP) and Alizarin red stainings were performed on cell 
cultures at the indicated times (n = 3). (E) ALP and Alizarin red intensity was measured using NIH ImageJ software (n = 3). (F) Real-time qPCR analyses were 
performed to determine the relative expression of Dnmt3b, Sp7, Runx2, and Alp in bone marrow–derived MPCs after 4 days osteogenic culture. The mRNA 
levels were normalized to that of Actb and then were normalized to the control group (n = 3). Data are presented as mean ± SD. *P < 0.05 by Student’s t test.
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Figure 4. Dnmt3b regulated mesenchymal progenitor cell differentiation via Rbpjκ-dependent Notch pathway. (A) Real-time qPCR analyses were 
performed to determine the relative expression of Dnmt3b, Sox9, HeyL, and Hey1 in mesenchymal progenitor cells (MPCs) isolated from E11.5 limb 
bud of Dnmt3bPrx1 embryos and control embryos. The mRNA levels were normalized to that of Actb and then were normalized to the control group 
(n = 3). (B) Western blot was performed to examine the protein level of Rbpjκ in MPCs from Dnmt3bPrx1 embryos and control embryos. Quantifi-
cation of the protein expressions was obtained using NIH ImageJ software (n = 3) (C) Real-time qPCR analyses were performed to determine the 
relative expression of Dnmt3b, HeyL, and Hey1 in bone marrow–derived MPCs from 10-week-old Dnmt3bPrx1 mice and control mice. The mRNA levels 
were normalized to that of Actb and then were normalized to the control group (n = 3). (D) Western blot was performed to examine the protein level 
of Rbpjκ in bone marrow–derived MPCs. Quantifications of the protein expressions were obtained using NIH ImageJ software. Data are presented as 
mean ± SD. *P < 0.05 by Student’s t test.
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Figure 5. Rbpjκ is a target of Dnmt3b. (A) A schematic representing 2 Dnmt3b binding sites (CpG islands, green box) identified in Rbpjκ gene. (B) Pull-
down of genomic DNA with a Dnmt3b antibody (ChIP assay) shows interaction of Dnmt3b with its binding site in the Rbpjκ promoter region by qPCR utiliz-
ing specific primers (n = 3). (C) Rbpjk promoter luciferase assay was performed in C3H10T1/2 cells with Dnmt3b loss of function (LOF) and gain of function 
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via DAPT treatment could enhance fracture repair through promoting MPC differentiation in wild-
type mice (3, 28). To further validate if  Rbpjκ-mediated Notch pathway is the critical downstream tar-
get of  Dnmt3b in the context of  fracture healing in mice, we first employed DAPT, the Notch inhibitor, 
to suppress Notch activation in cell cultures and in Dnmt3bPrx1 mice. Similar to Rbpjκ inhibition, Notch 
inhibition via DAPT in limb bud–derived MPCs substantially increased chondrogenic differentiation 
and cartilage matrix deposition, as reflected by enhanced ABH staining in Dnmt3bPrx1 micromass cell 
cultures following DAPT treatment (Supplemental Figure 6, A and B). In accordance with these obser-
vations, the expression of  chondrogenic regulatory gene, Sox9, and the cartilage-specific extracellular 
matrix molecules, Col2a1 and Agc1, were induced with expression levels higher than those observed in 
littermate controls under basal conditions (Supplemental Figure 6C). In bone marrow–derived MPC 
cultures, Notch inhibition with DAPT had a similar effect. DAPT treatment significantly stimulated 
the osteogenic differentiation and osteoblast mineral deposition in bone marrow–derived MPCs of  
Dnmt3bPrx1 mice (Supplemental Figure 6, D and E). Real-time qPCR revealed increased expression 
of  osteogenic genes, including Runx2 and Spp1, in bone marrow–derived MPCs of  DAPT-treated 
Dnmt3bPrx1 mice (Supplemental Figure 6F). We then treated control mice and Dnmt3bPrx1 mice with a 
single dose of  DAPT (50 mg/kg body weight) 2 dpf. Consistent with our previous finding (28), DAPT 
treatment significantly downregulated Notch pathway in both control mice and Dnmt3bPrx1 mice, as 
reflected by decreased Notch downstream genes, such as HeyL and Hey1 (Figure 6A). As expected, 
DAPT treatment stimulated cartilage tissue formation 10 dpf  and bone tissue formation 14 dpf  in 
control mice. More importantly, DAPT treatment also reversed chondrogenic and osteogenic differen-
tiation defect in Dnmt3bPrx1 mice during fracture healing. Histological analyses revealed an accelerated 
endochondral ossification process, including increased cartilage tissue 10 dpf  and bone tissue 14 dpf  
in DAPT-treated Dnmt3bPrx1 mice (Figure 6, B and C). Furthermore, micro-CT analyses of  mineralized 
calluses confirmed that DAPT treatment induced a robust bone formation in fractures of  Dnmt3b-
Prx1 mice, shown as increased bony callus volume 10 and 14 dpf, compared with the DMSO-treated 
group. DAPT treatment restored the bony callus formation in Dnmt3bPrx1 mice to a level comparable 
to that in DAPT-treated control mice (Figure 6, D and E). Interestingly, we also observed increased 
osteoclast activity in fractures of  DAPT-treated Dnmt3bPrx1 mice 14 dpf  compared with fractures of  
DMSO-treated Dnmt3bPrx1 mice (Supplemental Figure 7, A and B). Altogether, the results show that 
Dnmt3b induces chondrogenic and osteogenic differentiation in MPCs through a mechanism involv-
ing reduced Notch signaling and its expression is required for normal bone regeneration.
Discussion
Bone fracture repair occurs through a complex and integrated series of  events involving several transcrip-
tional responses unique to different cell types, including MPCs, chondrocytes, osteoblasts, and osteoclasts. 
The recruitment and differentiation of  endogenous progenitor cells to the fracture site is a key initial step in 
fracture healing. Although the cellular and molecular events regulating differentiation during bone regener-
ation have been studied in various cell populations and animal models (29), the epigenetic factors regulating 
regeneration are largely unknown. Recent epigenome screening of  human fracture tissues suggests that DNA 
methylation is involved in bone healing (14). Consistently, we showed a reduced Dnmt3b expression in frac-
ture calluses of  HFD-induced diabetic mice and aging mice. Thus, the present work is timely and reveals the 
critical effect of  Dnmt3b LOF on regulating MPC differentiation and bone repair.
We have previously established that Dnmt3b is the most regulated DNA methyltransferases during the 
endochondral bone regeneration process (20). Dnmt3b expression is induced in the early repair phase and 
is highly expressed in progenitor cell populations (20). In the present study, we provided additional evidence 
and demonstrated that Dnmt3b positively regulates chondrogenic and osteogenic differentiation of MPCs by 
using well-established primary embryonic limb bud–derived mesenchymal cells and bone marrow–derived 
mesenchymal cells (30, 31). In both cells, key transcription factors involved in chondrogenic and osteogenic 
(GOF) (n = 3). (D) Real-time qPCR analysis of Rbpjk, HeyL, Sox9, and Sp7 in C3H10T1/2 cells with Dnm3b LOF and Rbpjκ LOF. The mRNA levels were 
normalized to that of Actb and then were normalized to the control group (n = 3). (E) Alcian blue and alkaline phosphatase (ALP) stainings were performed 
to examine the chondrogenic and osteogenic processes, respectively (n = 3). (F) Alcian blue and ALP intensity was measured using NIH ImageJ software (n 
= 3). (G) Real-time qPCR analyses were performed to determine the relative expression of Agc1, Col2, Alp, and Spp1 in C3H10T1/2 cells. The mRNA levels 
were normalized to that of Actb and then were normalized to the control group. Data are presented as mean ± SD. *P < 0.05 by 1-way ANOVA test.
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differentiation, Sox9 and Sp7, respectively, were reduced by loss of Dnmt3b. In contrast, cell proliferation and 
apoptosis (less than 1%; data not shown) are not affected in MPC cultures, indicating that decreased progenitor 
cell differentiation capacity but not cell viability or impaired proliferation accounts for the reduced fracture 
callus formation. The findings were consistent with in vivo fracture experiments that demonstrated decreased 
chondrogenic and osteogenic differentiation and impaired fracture healing in Dnmt3bPrx1 mice. In addition to 
reduced secondary osteogenesis in association with the cartilaginous callus, there was also decreased osteogen-
esis along the periosteal bone surface adjacent to the fracture site where primary bone formation occurs, sug-
gesting a direct cell autonomous effect on osteoblast differentiation (22). We previously reported delayed bone 
remodeling in fractures of mice with conditional Agc1-Cre–mediated chondrocyte gene deletion (20). In the 
current study, we similarly show delayed bone remodeling in fractures with somatic Dnmt3b LOF in limb bud–
derived MPCs, with reduced numbers of osteoclasts in the early remodeling phase (14 dpf), but persistence of  
osteoclasts at later times (21 and 28 dpf) when remodeling had been completed in fractures of control mice. As 
the Prx1-driven gene deletion does not directly affect osteoclast precursors due to lack of Prx1 expression in 
these cells, the findings suggest that the reduced osteoclast differentiation is secondary to noncell autonomous 
signals from chondrocytes and/or osteoblasts. Finally, biomechanical testing, the most sensitive method to 
determine fracture healing, confirmed the impaired fracture healing in mice with Dnmt3b LOF in MPCs.
DNA methylation is highly responsive to environmental stimuli as it broadly regulates the expression 
of  growth factors, receptors, and transcription factors and coordinates signaling networks at the genome 
level (32, 33). TGF-β, BMP, Wnt/β-catenin, Notch, and IHH signaling pathways are established down-
stream targets of  DNA methylation (34–39). In current study, we demonstrated for the first time to our 
knowledge that the Rbpjκ-mediated Notch pathway is regulated via epigenetic alteration in the context of  
fracture repair. In vitro cell culture experiments identified Rbpjκ as a direct downstream target of  Dnmt3b 
since hypomethylation of  the Rbpjκ promoter and gene body occurred with loss of  Dnmt3b. This resulted 
in the upregulation of  Rbpjκ gene expression and an increase in Notch signaling in MPCs. Moreover, the 
2 Dnmt3b-binding regions in Rbpjκ (CpG islands) were found to be correlated with active histone mod-
ification in the University of  California, Santa Cruz genome browser, confirming that the 2 CpG islands 
are the important epigenetic regulatory loci (40). Importantly, Rbpjκ inhibition via lenti-shRNA restored 
chondrogenesis and osteogenesis in MPCs with Dnmt3b LOF, indicating the functional importance of  
Rbpjκ as a Dnmt3b target in the regulation of  cell differentiation. In addition to Rbpjκ, we recently iden-
tified hypomethylation in Cxcl12 gene in Dnmt3b LOF chondrocytes (20), suggesting Dnmt3b LOF could 
directly modify DNA methylation pattern in chondrocyte maturation–related genes. Findings from other 
groups also demonstrated that chondrogenic- and osteogenic-related genes could be regulated via alteration 
of  DNA methylation in promoters (41–43). We thus speculate Dnmt3b LOF leads to progenitor differenti-
ation defect through a combination of  an altered Notch pathway and the alteration of  DNA methylation in 
chondrogenic- and osteogenic-specific genes. A whole-genome bisulfite DNA methylation sequencing will 
be extremely helpful to probe all the differential methylated loci and comprehensively understand the role 
of  Dnmt3b-mediated epigenetic alteration in the regulation of  progenitor differentiation.
To confirm Rbpjκ as a Dnmt3b target in the context of fracture repair in vivo, we then treated Dnmt3bPrx1 
mice with a single dose of DAPT 2 dpf. Consistent with in vitro findings, transient inhibition of Notch by DAPT 
at least partially restored MPC differentiation and fracture repair in Dnmt3bPrx1 mice. Although we have previous-
ly demonstrated that a single dose of DAPT was sufficient to suppress Rbpjκ-mediated Notch pathway in wild-
type mice, with minimal side effects on progenitor cell recruitment during hematoma phase (28), it is still worth 
optimizing the injection regimen of DAPT to minimize its potential toxicity (44–46) and incessantly promoting 
the differentiation of progenitor cells, which can be continuously recruited to injury site via reestablished blood 
vessels and from adjacent periosteum tissue during the cartilaginous and bony callus phase (47). Furthermore, 
to fully elucidate the interaction between Dnmt3b and Rbpjκ in the context of progenitor cell differentiation and 
Figure 6. Notch inhibition via dual antiplatelet therapy restored fracture repair in Dnmt3bprx1 mice. (A) Notch pathway inhibition efficacy was determined 
by real-time qPCR. The mRNA expression of Dnmt3b, HeyL, and Hey1 was measured in fracture calluses of dual antiplatelet therapy–treated (DAPT-treated) 
and DMSO-treated control mice and Dnmt3bPrx1 mice 3 days after fracture (dpf). (B) Alcian blue/Hematoxylin/Orange G (ABH/OG) staining of fracture callus 
sections of DAPT- and DMSO-treated control and Dnmt3bPrx1 mice at the indicated times (n = 5). Scale bar: 500 μm. (C) Histomorphometry quantification of 
the cartilage and bone areas was performed on ABH/OG-stained fracture callus sections (n = 5). (D) Microcomputed tomography assessment of mineral-
ized bone in fracture calluses of DAPT- and DMSO-treated control mice and Dnmt3bPrx1 mice at the indicated times (n = 5). (E) Quantification of bony callus 
volumes 10 and 14 dpf (n = 5). Data are presented as mean ± SD. *P < 0.05 by 2-way ANOVA test.
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fracture repair, it would be better to generate Rbpjκ LOF mice under Dnmt3b LOF background since DAPT 
is not an Rbpjκ-specific inhibitor. DAPT can block γ-secretase and thus suppresses both canonical and nonca-
nonical Notch pathway (48). Given that sustained inhibition of Rbpjκ using Prx1Cre led to severe osteoporosis 
in adult mice and led to fracture nonunion primarily because ablation of Rbpjκ exhausted the progenitor pop-
ulation during skeletal development (3, 23, 49), doxycycline-induced ten-eleven translocation (Tet) system (50) 
should be considered to generate Dnmt3b; Rbpjκ double LOF mice and mimic the transient Rbpjκ inhibition 
effect. Primary MPCs isolated from these animals will provide more robust cellular and molecular insights into 
the mechanisms involved in the epigenetic regulation of MPC differentiation.
In the current study, we performed fracture surgeries on 10-week-old mice and confirmed the positive role 
of Dnmt3b in stimulating fracture repair in mice. Although 10-week-old mice are skeletally mature, they are 
relatively young animals for fracture studies, with robust healing capacity. Aged mice will experience more 
advanced fracture healing delay (51, 52) and are more clinically relevant. Clinical studies of patients have 
documented that aging and chronic diseases, in particular inflammatory conditions, compromise the normal 
healing process and sometimes lead to fracture nonunion by negatively affecting MPC differentiation (29, 
53–58). Therefore, it is worth examining the effect of Dnmt3b gain of function and Rbpjκ LOF in mice under 
aging or systemic inflammatory conditions, to provide novel cellular and molecular candidates for therapeutic 
intervention. Additionally, Dnmt3a is the other critical de novo enzymes, which has been reported to work 
synergistically with Dnmt3b to regulate events during embryonic development, for example, HSC differentia-
tion (18). Double knockout of Dnmt3a and Dnmt3b resulted in enhanced HSC self-renewal and blockage of cell 
differentiation, whereas single deletions of Dnmt3a and Dnmt3b results in a mild phenotype (17, 18), indicating 
the overlap role of Dnmt3a and 3b in regulating HSC differentiation. Similarly, Dnmt3bPrx1 mice display a mild 
limb phenotype in embryos (data not shown), and no gross bone phenotype is observed in adult animals, likely 
due to the compensatory effect of Dnmt3a or other DNA methylation enzymes in MPCs under physiology 
conditions. Therefore, it is worth determining the role of Dnmt3a and other demethylation enzymes, such as 
Tet, enzymes in the regulation of skeletal tissue homeostasis under challenging conditions.
In summary, we have defined a key role for Dnmt3b as a regulator of normal fracture repair. In normal 
fracture healing, Dnmt3b expression is increased, and this is associated with reduced Notch signaling and 
robust MPC differentiation along the chondrogenic and osteogenic bone-forming lineages. At the molecular 
level, we found that Dnmt3b deletion induced Rbpjκ expression, and the subsequent Notch activation inhibited 
MPC differentiation. Future studies will identify conditions in which altered Dnmt3b expression and DNA 
methylation lead to compromised fracture repair. We anticipate that Notch inhibition represents a potential 
new therapy for fracture repair defects associated with Dnmt3b LOF–induced Notch activation in MPCs.
Methods
Mice. Dnmt3bPrx1 mice were generated by breeding Dnmt3bf/f mice (59) (obtained from the Mutant Mouse 
Regional Resource Center, Davis, California, USA; 29887) with Prx1-Cre transgenic mice (60) (pur-
chased from Jackson Laboratory; 005584). Dnmt3bPrx1 mice were viable, fertile, and produced at expected 
Mendelian ratios. Unilateral tibial fracture procedures (20) were performed on 10-week-old Dnmt3bPrx1 
mice and their littermate controls. One dose of  DAPT (50 mg/kg; Enzo Life Science, catalog ALX-270-
416) or DMSO (vehicle) was given to Dnmt3bPrx1 mice via intraperitoneal injection 2 days after fracture 
to suppress Notch pathway.
Histological analyses of  fracture callus. The fractured tibia samples were collected for histological analyses 7, 
10, 14, 21, and 28 dpf (n = 5 per group in each time point). After mice were euthanized, the fractured tibiae 
were collected along with the adjacent tissues and fixed in 10% neutral buffered formalin (NBF) for 3 days and 
then decalcified for 10 days in 14% ethylenediaminetetraacetic acid solution (pH 7.2). Tissue was then sectioned 
longitudinally at a thickness of 5 μm. ABH/OG staining and TRAP staining were performed to analyze the 
callus composition and osteoclast formation in the fracture region. Sections were visualized with nanozoomer 
(NanoZoomer HT). Histomorphometric analyses were performed using NIH ImageJ software 1.46r (Wayne 
Rasband). Mesenchyme area, cartilage area, bone area, and osteoclast surface per bone surface (Oc. S/BS) 
were measured and calculated as previously described (28). In general, mesenchyme tissue had a fibroblastic 
appearance at the margin of fracture and was stained in light blue. Cartilage tissue comprised rounded-shaped 
chondrocytes and was stained in dark blue. Bony tissue was stained in red. IHC staining for Dnmt3b (Abcam, 
ab16049, 1:1000) was performed on paraffin sections following the antigen retrieval and colorimetric develop-
ment methodologies. Citrate buffer with high temperature and pressure antigen retrieval was used.
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Micro-CT analysis. After careful dissection and removal of the intramedullary pins in fractured tibiae, we 
examined the fracture calluses using the micro-CT (VivaCT 40, Scanco) scanner at 10.5 μm resolution (55 kV, 
145 μA, 300 ms integration time). Six hundred slices (6.3 mm) centered on the midpoint were used for micro-CT 
analyses. A contour was drawn around the margin of the entire callus and a lower threshold of 150 per mille 
was then applied to segment mineralized tissue (all bone inside the callus). A higher threshold of 460 per mille 
was applied to segment the original cortical bone inside the callus volume. Quantification for the volumes of  
the bone calluses was determined as previously described using the Scanco analysis software (n = 6 per group in 
each time point) (61). 3D images were generated using a constant threshold of 240 per mille for the diaphyseal 
callus region of the fractured tibia. The intact tibia samples from 10-week-old control mice and Dnmt3bPrx1 mice 
were also scanned at resolution 21 μm (70 kV, 114 μA, 300 ms integration time). Cortical bone was assessed at a 
region of interest centered 5 mm proximal to the distal tibiofibular junction, spanning 50 slices (1 mm). Trabec-
ular bone was assessed at the proximal metaphysis, distal of the growth plate, and spanned 200 slices (4.2 mm).
Biomechanical torsion testing. The fractured tibia bone samples harvested 28 dpf (n = 10 per group) were pot-
ted with methacrylate (MMA) bone cement (Lang Dental Manufacturing) and secured in 1.2-cm-long cylinders 
(6-mm diameter) to keep the fracture sites in the midinterval. After the MMA solidified, the bone samples with 
the cylinders were set up on the torsion machine and processed using the custom LabVIEW (National Instru-
ments) program. The data of torsion testing were present against the rotational deformation as the maximum 
torque, torsional rigidity, and energy to fracture using the custom MATLAB 2017b program (Mathworks).
Limb bud–derived mesenchymal cell isolation and micromass culture. Limb bud–derived MPCs were isolated 
from E11.5 Dnmt3bPrx1 embryos and control embryos (25). Briefly, the limb buds from embryos were dissect-
ed and digested with Trypsin (Life Technologies; 25200056) at 37°C for 5 minutes. MPC cell suspensions 
were filtered through a 0.4-μm cell strainer and reconstituted to the density at 2 × 107 cells/mL. MPC cell 
suspensions (10 μl) were seeded in the center of  24-well plates for 1.5 hours and then cultured in high-glu-
cose DMEM supplemented with 10% FBS (Life Technologies, catalog 26140079). For chondrogenic differ-
entiation, the micromasses were cultured with maturation medium, including 10 mM β-glycerophosphate 
(Sigma-Aldrich, catalog G9422) and 50 μg/mL ascorbic acid (Sigma-Aldrich, catalog A4544) for 3 days. We 
also used 10 μM DAPT(Calbiochem, catalog 565784 ) as a γ-secretase inhibitor to suppress Notch pathway 
during the micromass culture. Alcian blue staining was performed on micromasses to assess the chondrogen-
ic capacity of  MPCs in Dnmt3bPrx1 embryos and control embryos. After 30 minutes fixation with 10% NBF, 
the micromass cultures were stained with 1% Alcian blue solution for 30 minutes and then rinsed with 70% 
ethanol. After washing 3 times with ddH2O, images were captured by scanner (EPSON, Perfection 1660).
Bone marrow–derived mesenchymal cells isolation and culture. Bone marrow–derived MPCs were isolated 
from 10-week-old Dnmt3bPrx1 mice and control mice. Both femur and tibia were dissected, and bone mar-
row–derived cells were centrifuged into the 1.5-mL tube from the marrow cavity. MPCs were then seeded 
on a 100-mm tissue culture dish in MEM-α (Life Technologies, catalog A1049001) containing 10% FBS 
(Gibco, catalog 16000044), and 1% Penicillin-Streptomycin (Thermo Fisher, catalog 15140122). Nonad-
herent cells were removed after 3 days of  culture and MPCs were cultured and expanded until 70% conflu-
ency. The cells (4 × 105 cells per well) of  Dnmt3bPrx1 mice and control mice were plated for 14 days without 
change of  mouse MSC medium (StemCell Technologies, catalog 05513) for colony-forming unit assay. 
Crystal violet staining was performed and type I colonies were quantified as previously described (23). 
For osteogenic differentiation, MPCs were seeded at a density of  4 × 105 cells/mL in osteogenic medium, 
including 10 mM β-glycerophosphate and 50 μg/mL ascorbic acid. We also used 10 μM DAPT (Calbio-
chem; 565784) as a γ-secretase inhibitor to suppress Notch pathway during osteogenic differentiation. ALP 
staining and Alizarin red staining were performed on cell cultures to assess the osteogenic capacity of  
MPCs from Dnmt3bPrx1 and control mice at indicated time points. Briefly, after 10% NBF fixation, the cell 
cultures were stained with the NBT/BCIP substrate solution (cccccg) to detect ALP activity or alizarin red 
solution (Sigma-Aldrich, catalog A5533) to detect mineral deposition. After washing 3 times with H2O, 
images were captured by scanner (EPSON, Perfection 1660).
C3H10T1/2 cell culture and differentiation. C3H10T1/2 cells (ATCC CCL-226) were infected with Len-
ti-shDnmt3b virus (multiplicity of  infection [MOI] = 50, Origene, catalog TL508059V) and Lenti-shRb-
pjκ virus (ΜΟΙ = 50; Origene, catalog ΤL512813V), respectively, to knock down Dnmt3b and Rbpjκ 
expression in cells. C3H10T1/c cells were cultured in chondrogenic medium for 14 days and osteogenic 
medium for 7 days. Alcian blue and ALP stainings were used to examine the chondrogenic and osteo-
genic differentiation processes.
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ChIP assay. C3H10T1/2 cells (1 × 107) were harvested and fixed with formaldehyde for ChIP assays. 
Chromatin was fragmented by sonication to shear DNA to 200–500 bp in size. Chromatin fragments 
were immunoprecipitated using the Dnmt3b antibody (1:50, Abcam, ab2851), whereas Histone H3 and 
IgG antibodies were used as positive and negative controls, respectively. After reverse crosslinking of  
protein-DNA, the enrichment of  Rbpjκ DNA fragment during immunoprecipitation was analyzed by 
quantitative real-time PCR. Primer sequences used for CpG Island 1 in Rbpjκ promoter were forward, 
5′-CTAGGTGACTCAGATGCATGAC-3′, and reverse, 5′-TCCCGAGCCTGGTACTT-3′; primer 
sequences for CpG Island 2 in Rbpjκ gene body were forward, 5′-CCTTTGTTTCGCCGCCTTA-3′, and 
reverse, 5′-CCAGCTACTGAAGAGAGGGATA-3′.
Methylation qPCR. Methylation qPCR for Rbpjκ was performed according to the manufacturer’s instruc-
tion (QIAGEN). Genomic DNA isolated from limb bud–derived MPCs in Dnmt3b LOF and control mice 
was enzymatically digested by methylation-sensitive or methylation-dependent enzyme separately. The 
enzyme-digested genomic DNA was then used for qPCR and the primers for Rbpjκ methylation (CpG 
Island 106810 and 106811) were obtained from QIAGEN (EPMM106810 and EPMM106811).
Rbpjκ promoter luciferase assay. C3H10T1/2 cells were transfected with Cignal Lenti RBPJκ luciferase 
reporter (QIAGEN) with MOI of  5 and then cultured under 2 μg/mL puromycin selection. The stable 
C3H10T1/2 cells were transfected with lentivirus to inhibit or overexpress Dnmt3b for 24 hours before 
performing the luciferase assay.
Real-time qPCR and Western blot. RNA was isolated from primary cell cultures or C3H10T1/2 cells using 
RNeasy Mini Kit (QIAGEN). RNA was also isolated from fracture calluses of  HFD-induced mice and 
18-month-old wild-type mice 7 dpf  as well as fracture calluses of  DMSO- and DAPT-treated control mice 
and Dnmt3bPrx1 mice 3 dpf. Four millimeters of  fracture calluses were flushed of  morrow and homogenized 
for mRNA extraction. cDNA synthesis and real-time RT-PCR was performed according to the manufac-
turers’ instructions. Primer sequences for Dnmt3b, Sox9, Col2a1, Agc1, Sp7, Runx2, Spp1, Alp, HeyL, Hey1, 
and Actb are detailed in Table 1. Western blot analyses were performed on the protein lysates from limb 
bud–derived or bone marrow–derived MPCs. The following primary antibodies were used: Rbpjκ (Cell 
Signaling, 5313, 1:1000) and Actb (Sigma-Aldrich, 2228, 1:2000). Quantification of  the protein expressions 
(relative intensity) was measured using NIH ImageJ 1.46r software.
Table 1. Primer sequences for real-time qPCR
Genes Sequences
Dnmt3b
5′-AATACCCAACTCCTTGAGCAC-3′
5′-TCTTCACTACTGATCCTGACCT-3′
Sox9 
5′-CGGCTCCAGCAAGAACAAG-3′
5′-TGCGCCCACACCATGA-3′
Col2a1
5′-GCAGAGATGGAGAACCTGGTA-3′
5′-AGCCTTCTCGTCATACCCT-3′
Agc1
5′-CGTGTTTCCAAGGAAAAGGA-3′
5′-TGTGCTGATCAAAGTCCA G-3′
Sp7 
5′-CTTCTTTGTGCCTCCTTTCC-3′
5′-GCGTCCTCTCTGCTTGA-3′
Runx2
5′-CGTCCACTGTCACTTTAATAGCTC-3′
5′-GTAGCCAGGTTCAACGATCTG-3′
Alp 
5′-TGACCTTCTCTCCTCCATCC-3′
5′-CTTCCTGGGAGTCTCATCCT-3′
Spp1
5′-TCGTCATCATCGTCGTCCA-3′
5′-AGAATGCTGTGTCCTCTGAAG-3′
HeyL
5′-CAGCCCTTCGCAGATGCAA-3′
5′-CCAATCGTCGCAATTCAGAAAG-3′
Hey1
5′-GCGCGGACGAGAATGGAAA-3′
5′-TCAGGTGATCCACAGTCATCTG-3′
Actb 
5′-AGATGTGGATCAGCAAGCAG-3′
5′-GCGCAAGTTAGGTTTTGTCA-3′
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Statistics. Statistical analyses were performed using GraphPad Prism. Comparisons between 2 groups 
were performed using 2-tailed, unpaired Student’s t test and 1- or 2-way ANOVA followed by Tukey test to 
compare multiple groups under different genotypes or under different treatments at multiple time points. 
All data are presented as the mean ± SD. P values of  less than 0.05 were considered statistically significant.
Study approval. Unilateral tibial fracture procedures were performed in compliance with Washington 
University’s Institutional Animal Care and Use Committee, accredited by the Association for Assessment 
and Accreditation of  Laboratory Animal Care International, and the NIH guidelines.
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